Good Clinical Practice (GCP) is an international ethical and scientific quality standard for the planning, conduct, documentation, and reporting of clinical trials involving human subjects. GCP ensures that the rights, safety, and well-being of trial participants are protected, and that the clinical data collected are credible and verifiable. In the EU, GCP is legally enshrined through Regulation 536/2014 on clinical trials and the ICH Guideline E6(R3).
Historical Development and Legal Framework
The roots of GCP lie in the Declaration of Helsinki (1964) by the World Medical Association, which first established ethical principles for medical research involving human subjects. Based on this, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) developed the first harmonized GCP Guideline E6 from 1990 onwards, which was adopted in 1996.
With the revision to ICH E6(R2) in 2016, the concept of a risk-based approach (Risk-Based Monitoring) was introduced. The currently valid version, ICH E6(R3), was finalized in 2023 and strengthens requirements for data integrity, electronic systems, and decentralized clinical trials. In Germany, GCP is implemented into national law via the German Medicines Act (Arzneimittelgesetz – AMG) §§ 40–42a and the GCP Regulation.
Core Principles of GCP
GCP is based on 13 fundamental principles defined in ICH E6. The most important ones in daily CRO operations are:
- Benefit-Risk Assessment: Clinical trials are only ethically justifiable if the expected benefits outweigh the risks
- Informed Consent: Every participant must voluntarily consent after full disclosure before the start of the study
- Qualification of Trial Personnel: Investigators and the trial team must be qualified through training and experience
- Protocol Compliance: All study processes must be conducted according to the approved clinical trial protocol
- Data Integrity (ALCOA Principles): Data must be attributable, legible, contemporaneous, original, and accurate
- Confidentiality: Personal participant data must be protected in accordance with data protection law
GCP Requirements for Sponsor and Investigator
GCP clearly distinguishes between the responsibilities of the sponsor (who initiates and finances the clinical trial) and the investigator (who conducts the trial at the trial site).
The sponsor is responsible for: creating and maintaining the Trial Master File (TMF), implementing a quality management system, monitoring (including risk-based monitoring), safety reporting (SUSAR notifications), contracting with trial sites, and ensuring compliance with all regulatory requirements. These tasks are often delegated to a Contract Research Organization (CRO) – although overall responsibility remains with the sponsor.
The investigator is responsible for: recruiting and informing participants, correctly performing trial procedures, documenting all observations in the Case Report Form (CRF), reporting adverse events, and retaining Essential Documents at the trial site.
GCP-Compliant Documentation
Complete documentation is at the heart of GCP compliance. All study-relevant documents are compiled in the Trial Master File (TMF) – at the sponsor/CRO and at the trial site. The electronic data capture system (eCRF/EDC) must be validated (Computerized System Validation). Original data (Source Data) must not be altered retrospectively; every change must be documented with date, initials, and justification (Audit Trail). The retention period for Essential Documents is at least 25 years after study completion for registration studies.
GCP Monitoring and Audits
Clinical monitoring is a central GCP instrument. The sponsor must ensure that data are collected correctly and completely. According to ICH E6(R3) and EU Regulation 536/2014, monitoring can be risk-based: central data analyses (Central Monitoring) replace or supplement on-site visits (On-Site Monitoring). Standard Operating Procedures (SOPs) define the exact monitoring processes.
Audits and inspections verify GCP compliance. While audits are conducted internally by the sponsor or a CRO, authorities such as the Federal Institute for Drugs and Medical Devices (BfArM), the Paul-Ehrlich-Institut (PEI), or the European Medicines Agency (EMA) conduct official inspections. Deficiencies can lead to the rejection of marketing authorization applications.
Relevance for clinical trials
GCP is the foundation of every regulatory-usable clinical trial. Without GCP-compliant data, neither EMA nor BfArM will accept a marketing authorization application. Full-service CROs like mediconomics implement GCP-compliant processes across all study phases – from protocol development and monitoring to archiving study documentation in accordance with Trial Master File requirements.
Frequently Asked Questions (FAQ)
What is the difference between GCP and GMP?
Good Clinical Practice (GCP) regulates the conduct of clinical trials in humans – i.e., study planning, monitoring, data collection, and patient protection. Good Manufacturing Practice (GMP), on the other hand, regulates the manufacturing of medicinal products and investigational medicinal products under defined quality conditions. In a clinical study, GMP applies to the manufacturing of the investigational medicinal product, while GCP applies to the conduct of the trial itself.
Is ICH E6(R3) already applicable in the EU?
ICH E6(R3) was finalized by the ICH in 2023 and recommended for implementation by the EMA. In the EU, the guideline is being gradually integrated into the regulatory framework. For new clinical trials, it is advisable to already consider the requirements of E6(R3) – especially regarding data integrity, risk-based monitoring, and decentralized studies – as authorities increasingly expect these principles during inspections.
What happens during a GCP inspection by BfArM or EMA?
During a GCP inspection, authority representatives review study documentation at the trial site and at the sponsor/CRO. They examine: consent documentation, Trial Master File, CRF data, monitoring reports, SOPs, and safety reports. Critical findings can lead to the rejection of submitted study data in the marketing authorization procedure. Therefore, meticulous GCP-compliant documentation is essential.
Regulatory References
- ICH E6(R3) (2023): Current GCP guideline; regulates risk-based monitoring, data integrity, and decentralized studies
- EU Regulation 536/2014 (CTR): Legally binding framework for clinical trials in the EU; applicable since January 31, 2022
- AMG (German Medicines Act, Germany): §§ 40–42a; national implementation of GCP requirements
- GCP Regulation (Germany, 2004, last amended 2022): Specifies GCP requirements for trials conducted in Germany
- Declaration of Helsinki (WMA, last revised 2024): Ethical principles for medical research involving human subjects
- EMA/CHMP/ICH/135/1995: Official EMA adoption decision of the ICH E6 GCP Guideline